tbuckley/cabot-search huggingface dataset:
AB0635 VASCULITIS IN RHEUMATOID ARTHRITIS: MULTIPLE FACETS TO LOOK FOR!
Authors: S. Rekik, A. Ben Amou, S. Rahmouni, K. Zouaoui, M. Abbes, H. Sahli, S. Boussaid, M. Elleuch
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Vasculitis in rheumatoid arthritis has a heterogeneous clinical presentation that includes skin disorders, neuropathy, and systemic inflammation. Rheumatoid vasculitis (RV) is an uncommon complication, that occurs in approximately 2 to 5% of patients who have Rheumatoid arthritis (RA). Rheumatoid vasculitis remains a serious complication with a grim prognosis caused by an increase in morbidity and mortality. <h3>Objectives:</h3> The objective of our study was to describe clinical features of RA complicated with vasculitis. <h3>Methods:</h3> We performed a retrospective study over 10 years enrolling data of patients presenting a rheumatoid vasculitis in a rheumatology department. <h3>Results:</h3> A total of 100 patients with RA were included, 84% were females. The mean age was 52 years. The prevalence of rheumatoid vasculitis was 11%. Diagnosis is made with a combination of symptoms, physical examination, pertinent laboratory tests, and tissue biopsy. Clinical presentation was heterogenous, skin involved in 63,6%, kidney (18%), central nervous system vasculitis (9%), and retinal vasculitis (9%). The mean duration between the diagnosis of RA and the onset of vasculitis was 11 years. RV occurred mainly in females (81,8%). A positive Rheumatoid Factor and/or anti-CCP antibodies were noted in 72% of cases. Disease activity was high in most cases, the average DAS28 score was 6,11. Patients have rheumatoid nodules in 27%. Most patients had extra-articular manifestations, presented on a secondary Sjogren's syndrome (36,3%), interstitial lung syndrome (27,2%), and worsening health status (54,5%). <h3>Conclusion:</h3> Although clinically rare, rheumatoid vasculitis is common at autopsy (about 25%). This suggests a careful search for this disease in order to improve the prognosis. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1012 THE SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS (SLICC) FRAILTY INDEX (SLICC-FI) PREDICTS HOSPITALIZATIONS IN A PREVALENT LATIN AMERICAN LUPUS COHORT
Authors: M. F. Ugarte-Gil, R. V. Gamboa-Cardenas, V. Pimentel-Quiroz, C. Reátegui-Sokolova, C. Elera-Fitzcarrald, C. Pastor Asurza, Z. Rodriguez Bellido, R. Perich Campos, G. S. Alarcón
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Frailty, measured with the SLICC-FI, has been reported as a predictor of damage in several cohorts. <h3>Objectives:</h3> To evaluate the SLICC-FI as a predictor of hospitalization in systemic lupus erythematosus (SLE) patients. <h3>Methods:</h3> Patients from a single-center prevalent cohort were included. The SLICC-FI was measured at baseline. Hospitalizations were reported during the first two years after the baseline visit as their number as well as their duration. Univariable and multivariable negative binomial regressions were performed to determine the association between the baseline SLICC-FI (per 0.05 increase) and hospitalizations during follow-up (number and length), adjusted for sex, age at diagnosis, socioeconomic status, educational level, disease duration, SLE Disease Activity Index 2000 (SLEDAI-2K), SLICC damage index (SDI), prednisone daily dose, antimalarial and immunosuppressive drug use at baseline. <h3>Results:</h3> Of the 302 patients included 280 (92.7%) were female, with mean (SD) age at diagnosis of 34.6 (7.2) years. At baseline, the mean (SD) disease duration was 7.2 (6.4) years, and the mean (SD) SLICC-FI was 0.21 (0.05). The mean number of hospitalizations per patient was 0.5 (1.6) and the mean number of days hospitalized during the two-year period per patient was 5.3 (16.8) days; 58 (17.9%) of the patients were hospitalized at least once during the follow-up. The SLICC-FI predicted a higher probability of hospitalizations as well as with a higher number of hospitalizations; these data are depicted in Table 1. <h3>Conclusion:</h3> The SLICC-FI predicts hospitalizations in SLE patients, independently of other well-known risk factors of hospitalizations. Further studies are needed to determine strategies to improve frailty in SLE patients. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> Manuel F. Ugarte-Gil GSK, AztraZeneca, AztraZeneca, Ferrer, Janssen, Rocío V. Gamboa-Cardenas: None declared, Victor Pimentel-Quiroz: None declared, Cristina Reátegui-Sokolova: None declared, Claudia Elera-Fitzcarrald: None declared, Cesar Pastor Asurza: None declared, Zoila Rodriguez Bellido: None declared, Risto Perich Campos: None declared, Graciela S. Alarcón: None declared.
AB0122 TREATMENT SEQUENCE PATTERNS OF URATE-LOWERING THERAPY FOR GOUT BASED ON A COMMON DATA MODEL
Authors: M. J. Kim, E. G. Park, D. Y. Kang, B. Ryu, K. Shin
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Treat-to-target strategy for gout has led to better outcomes and quality of life in patients. However, it encloses limited information on the optimal treatment strategy following the treatment failure of an initial urate-lowering agent (ULA). <h3>Objectives:</h3> To investigate the treatment sequence patterns of ULAs in the patient with gout. <h3>Methods:</h3> This study utilized electronic health record-based data from two centers distally located in Korea (BMC, UUH). Both databases were standardized based on a Common Data Model. Participants included patients 18 years or older with a diagnosis of gout and those who had at least 2 years of follow-up data between 2010 to 2022. Outcomes were the prescription frequency of different ULAs (allopurinol, febuxostat, and benzbromarone), as well as the sequence of the agents received in the line of therapy. A switch to, or addition of, a new ULA was considered a new line of therapy. Subgroup analyses were performed centered on baseline serum urate levels and comorbidities. <h3>Results:</h3> A total of 2743 eligible patients were identified in the two databases (1317 patients from BMC and 1426 patients from UUH). At BMC, febuxostat was the most prescribed medication, representing 55.2% of the initial treatment; 87.7% of patients continued the agent. For second-line therapy to febuxostat, more patients switched to allopurinol (63.1%) than either adding or switching to benzbromarone (36.9%). Meanwhile, half of the patients who initiated allopurinol switched to febuxostat, and 96.6% of these patients continued using febuxostat. At UUH, allopurinol was the dominant first-line agent (49.5%); 98% of switchers from allopurinol to febuxostat continued the agent, while 69% of those who either added or switched to benzbromarone from allopurinol changed to febuxostat in the subsequent lines of therapy. In both databases, patients with a high baseline serum urate level (≥9 mg/dL) tended to switch from allopurinol to febuxostat than the overall population (60% <i>vs</i>. 50% at BMC; 62% <i>vs</i>. 54% at UUH). There were allopurinol users with end-stage renal disease that switched to febuxostat (20.7% at BMC; 38.9% at UUH), but not vice versa. <h3>Conclusion:</h3> Our study shows the difference in first-line ULA between centers, yet febuxostat eventually was the predominantly used ULA in real-world practice. Furthermore, the sequence of urate-lowering therapy varied depending on the initial agent, baseline serum urate level, or renal function. <h3>REFERENCES:</h3> [1] Fernando Perez-Ruiz, Aitana Moreno-Lledó, Irati Urionagüena, Alastair J. Dickson, Treat to target in gout, Rheumatology, Volume 57, Issue suppl_1, January 2018, Pages i20–i26. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1237 PREVALENCE AND PREDICTIVE VALUE OF SYSTEMIC SCLEROSIS-ASSOCIATED ANTIBODIES: A SOUTH-ITALY MULTICENTER EXPERIENCE
Authors: G. Cuomo, C. Iandoli, D. Perretta, I. Sorriso, M. C. Visconti, C. Volpicelli, M. De Luca, C. Naclerio, F. Ciccia, C. Romano
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Systemic sclerosis (SSc) is a heterogeneous autoimmune disorder with high morbidity and mortality rates. SSc-associated autoantibodies are important diagnostic and predictive biomarkers of distinct clinical subtypes and internal organ manifestations. Despite variable antibody prevalence between different geographic regions, their clinical associations remain consistent. <h3>Objectives:</h3> The aim of this study was to assess the clinical and immunological features of a South-Italy multicenter SSc cohort. <h3>Methods:</h3> A retrospective cohort study of 895 SSc patients was conducted. Clinical and laboratoty data was collected from unique database of Campania and analyzed by means of descriptive and inferential statistics (Chi-square test for Indipendence, Relative Risk/RR). In this study la prevalence of antinuclear (ANA), anti-topoisomerase (anti-TOPO I/anti-Scl70) and anti-centromere (ACA) antibodies was evaluated, as well as their association with specific clinical phenotypes and organ system involvement. <h3>Results:</h3> 2013 ACR/EULAR classification criteria were fulfilled in all case. The mean of follow-up was 96.5 months. Female to male ratio was 7:1; with 68% with limited-SSc (lcSSc) vs 32% diffuse (dcSSc). ANA were negative in 1 patient. The most frequently autoantibodies found was ACA (57%), followed by anti-Scl-70 (35%). A significant relationship between anti-TOPO I and dcSSC was identified (p&lt;0.0001); patients with these antibodies had almost three-fold risk developing diffuse pattern during disease course (RR=2.95; 95%CI 1.62-4.86) and cardiac involvement (RR=2.42, 95% CI 1.88-3.23) and progressive lung fibrosis (RR=3.2 95%CI 1.99-4.55); ACA proved to be a statistically significant (p-value &lt;0.0001) risk factor for lcSSc with a RR= 2.65, 95%CI: 1.92-2.34); and risk factor for pulmonary arterial hypertension (PAH) (RR= 2.55, 95%CI 1.25-3.48). <h3>Conclusion:</h3> this study acknowledges the strong association between anti-TOPO-I and dcSSc, as well as relationship between ACA and lcSSc. Anti-TOPO-I is a known risk factor for the development of progressive lung fibrosis and cardiac involvement and therefore these patients should be actively screened for interstitial pulmonary involvement and cardiac dysfunction <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> Lega Italiana Sclerosi Sistemica. <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1224 SYSTEMIC SCLEROSIS AND COURSE OF PREGNANCY - RESULTS FROM THE NATIONWIDE PREGNANCY REGISTER RevNatus
Authors: B. Jakobsen, H. Koksvik, T. T. Pedersen, M. Wallenius
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Systemic sclerosis (SSc) is a rare systemic autoimmune disease characterized by widespread vascular dysfunction and progressive fibrosis of the skin and internal organs. Most previous reports on pregnancies in SSc are based on smaller retrospective collected cohorts and case reports [1]. <h3>Objectives:</h3> To describe the course of pregnancy in patients with SSc. <h3>Methods:</h3> We prospectively collected data on pregnancy outcomes in women with SSc through the nationwide Norwegian quality registry on pregnancy and rheumatic diseases (RevNatus) from 2017 – 2023. The women in this cohort were diagnosed with IDC-10 codes M34.0 (4), M34.1 (5), M34.8 (2) and M34.9 (7). 18 pregnancies in 17 women were recorded. <h3>Results:</h3> Median maternal age at birth was 34 years (SD = 4.2) and median disease duration was 4,5 years (SD = 7.9). 72 % were ANA positive, 39 % were anticentromere antibody positive and one women was positive for anti-topoisomerase I antibody. Six women had additional diseases; four had metabolic disease, one had psychiatric disease and one had inflammatory bowel disease. Two pregnancies were not planned. All pregnancies ended in live births with median gestational age at delivery of 38 weeks (range 28-42). Median birth weight was 2999 gram (SD = 632.6). 14 (78 %) had vaginal deliveries and 4 (22 %) had caesarean section (3 acute and 1 planned). One woman experienced preeclampsia and HELLP. Due to different and multiple scoring points during pregnancy we present mean of the highest reported values; self-reported patient global health 44.8 (SD 33.2), self-reported pain 29.3 (SD 22.7) and self-reported fatigue 53.3 (SD 26.4) on a visual analogue scale 0-100. <b>Table 1.</b> Pregnancy outcomes in 18 SSc pregnancies <h3>Conclusion:</h3> In this nationwide cohort with women with SSc we registered 4 pregnancies that resulted in preterm birth (≤ pregnancy-week 37). All pregnancies resulted in live births. However, SSc is a very heterogeneous disease, and only one patient had anti-topoisomerase I antibody. Our data support that women without serious organ manifestations may have uncomplicated pregnancies. <h3>REFERENCES:</h3> [1] Lazzaroni MG, Crisafulli F, Moschetti L, Semeraro P, Cunha AR, Neto A, Lojacono A, Ramazzotto F, Zanardini C, Zatti S, Airò P, Tincani A, Franceschini F, Andreoli L. Reproductive Issues and Pregnancy Implications in Systemic Sclerosis. Clin Rev Allergy Immunol. 2023 Jun;64(3):321-342. doi: 10.1007/s12016-021-08910-0. Epub 2022 Jan 18. PMID: 35040084. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1225 COMPARISON OF THE ACUTE EFFECTS OF INTRAVENOUS ILOPROST ON FINGER POWER DOPPLER ULTRASOUND IN SCLERODERMA PATIENTS IN TWO INFUSION 4 WEEKS APART
Authors: P. Macchioni, L. Magnani, S. Testoni, C. Tomassini, A. Laneri, C. Salvarani
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> In a previous study we have demonstrated that powerDoppler US (PDUS) is able to detect the iloprost (ILO) acute effect on subcutaneous vascularization of periungual (PU) and finger pulp (FP) subcutaneous areas in SSc patients with long-lasting disease. Few studies have explorated the chronic effect of ILO infusion in this group of patient. <h3>Objectives:</h3> We aim to evaluate the variation of the acute vascular effects of ILO infusion at baseline (T0) and at the second ILO infusion 4 weeks apart (T1). <h3>Methods:</h3> Twenty-eight consecutive SSc patients who met the ACR/EULAR criteria for SSc referring to our tertiary center for ILO infusion were enrolled in the study. FP and PU vascularization of the 1st, 2nd and 3rd finger of the dominant hand were evaluated before (ILO-B) and after (ILO-A) ILO infusion (dosage 0.5-2.0 ng/kg/min for 4-6 hours) at baseline (T0) and at ILO infusion 4 weeks later (T1) using an Esaote MylabClassC, (Genoa, Italy) machine equipped with a 22-8 Mhz multifrequency linear probe. All the exams were performed after at least 30 minutes of acclimatation in a room with an ambient temperature ranging from 20 to 24 ° C by the same operator (PM). All the images with the highest presence of PD signal were stored for subsequent examination by a rheumatologist (ST) blind to images sequency. The presence of PD signal in every image was scored according to a semiquantitative 0-5 scale. The value of each finger (FP &amp; PU) were summed up to obtain a total patient PD score (TotPDS). No improvement in TotPDS score was defined when the difference between ILO-A and ILO-B TotPDS (Δ TotPDS) was &lt; 0; while improvement was considered when Δ TotPDS was &gt; 1. Values of TotS and its variations (ILO-B minus ILO-A) at T0 and T1 were compared by T-test for paired samples. Clinical demographic and US data entered in a multivariate logistic regression analysis to evaluate the presence of factors predictive of TotS variation at T0 and T1. <h3>Results:</h3> Clinical and laboratory features of the 28 enrolled pts are reported in Table 1. TotPDS variations after the 1st and 2nd ILO infusion are reported in table 1. There were no statistical differences between ILO-B and ILO-A TotPDS at T0 and T1 examination. T0 Δ TotPDS was statistically lower than T1 Δ TotPDS. T1 Δ TotPDS was grater than T0 Δ TotPDS in 17 pts (60.7%), unchanged or lower in 11 pts (39.3%). At multivariate logistic regression analysis no baseline clinical, demographic or US characteristics of the patients were predictive of the TotPDS positive variation between T0 and T1 ILO infusion. <h3>Conclusion:</h3> PDUS examination of the PU and FP area can demonstrate an ILO chronic effect in SSc patients with long-lasting disease. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0101 PRECLINICAL IN VITRO AND IN VIVO EFFICACY STUDIES OF TIGULIXOSTAT, A SELECTIVE NON-PURINE XANTHINE OXIDASE INHIBITOR
Authors: A. Kumar, D. W. Kim, S. Kim
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Gout is a type of arthritis caused by the buildup of uric acid crystals in the joints, leading to inflammation and pain. Xanthine oxidase (XO) inhibitors, such as allopurinol (ALO) and febuxostat (FBX), are the current standard of care for lowering serum urate levels in patients with gout. Tigulixostat (TGX) is a potent and highly selective non-purine based XO inhibitor being investigated for the management of hyperuricemia in patients with gout. <h3>Objectives:</h3> To evaluate the in vitro and in vivo preclinical efficacy of TGX, along with the effect of TGX on pyrimidine metabolism. <h3>Methods:</h3> Bovine milk xanthine oxidase and rat plasma were used for in vitro xanthine oxidase assay. For evaluation of IC<sub>50</sub>, bovine milk xanthine oxidase was incubated with xanthine in the presence and absence of the test compound at room temperature. Uric acid formation was determined by spectrophotometer. Potency in rat plasma was measured by xanthine/xanthine oxidase assay kit. IC<sub>50</sub> of FBX and TGX in both studies were calculated with a non-linear best-fit regression model. In vivo studies, hypouricemic effect of FBX and TGX was evaluated in potassium oxonate (uricase inhibitor) induced hyperuricemia rat model. Rats were intraperitoneally injected with potassium oxonate (300 mg/kg) 1h before the test compound administration. Concentration of test compounds and uric acid were measured in plasma and liver. To test the effects on pyrimidine metabolism and kidney toxicity, ALO, FBX, and TGX at 100, 300 mg/kg or vehicle were orally administered to Balb/c mice. Blood samples were collected 24hr after drug administration and plasma concentration of orotic acid (OA), orotidine (OD), creatinine (Cr), and blood urea nitrogen (BUN) were measured. <h3>Results:</h3> IC<sub>50</sub> values of FBX and TGX in bovine milk were 0.003µM and 0.003µM, respectively. In rat plasma assay, IC<sub>50</sub> were 0.154µM and 0.073µM, respectively. Both compounds showed a hypouricemic effect in potassium oxonate-pretreated rats which EC<sub>50</sub> values of FBX and TGX were 0.34 μg/ml and 0.39 μg/ml, respectively. In normal Balb/c mice, plasma OD and OA increased 24hrs after administration of high dose (100 or 300mg/kg) of ALO, but remained unchanged after administration of FBX or TGX. FBX and TGX also showed no changes of Cr and BUN, the indicator of kidney toxicity. <h3>Conclusion:</h3> In preclinical evaluation of efficacy, TGX inhibited XO enzyme activity and lowered uric acid at a level comparable to febuxostat. In addition, TGX, with no structural resemblance to purine base, does not affect the pyrimidine metabolism and its related kidney toxicity in mice. <h3>REFERENCES:</h3> <b>NIL</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0645 CHOROIDAL VASCULARITY INDEX AND SUBFOVEAL CHOROIDAL THICKNESS IN RHEUMATOID ARTHRITIS ASSESSED WITH ENHANCED-DEPTH IMAGING OPTICAL COHERENCE TOMOGRAPHY
Authors: M. Berhuni, F. Albayrak
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Systemic vasculitis due to rheumatoid arthritis can also affect the choroidal tissue, which has a rich vascular network. Retinal vasculitis and choroiditis can be seen in rheumatoid arthritis. <h3>Objectives:</h3> To evaluate the effects of rheumatoid arthritis (RA) on choroidal vascularity index (CVI) and subfoveal choroidal thickness (SFCT). <h3>Methods:</h3> The study included 56 eyes of 28 rheumatoid arthritis patients and 65 eyes of 65 age- and sex-matched healthy normal participants. CVIs of all participants were measured by transferring enhanced depth imaging optical coherence tomography (EDI-OCT) images to the image J program and compared between the 2 groups. SFCT, central macular thickness (CMT) and optic disc parameters of all participants were measured with spectral domain OCT and compared. <h3>Results:</h3> The mean CVI values of the RA and control groups were 65.9±1.52 and 68.56±1.62, respectively, and were significantly lower in the RA group (p:0.001). Mean SFCT values of the RA and control groups were 290.11±15.18 and 332.88±11.04, respectively, and SFCT was significantly lower in the RA group (p:0.001). There was no significant difference between the two groups in terms of CMT and optic disc parameters. <h3>Conclusion:</h3> RA patients have lower CVI and thinner SFCT than healthy participants. <h3>REFERENCES: NIL.Acknowledgements:</h3> I thank all the authors for their contributions. <h3>Disclosure of Interests:</h3> <b>None declared.</b>